Rockwell Medical (NASDAQ:RMTI) Price Target Lowered to $7.00 at HC Wainwright

Rockwell Medical (NASDAQ:RMTI) had its price target lowered by HC Wainwright from $9.00 to $7.00 in a research report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently commented on the stock. RODMAN&RENSHAW raised shares of Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw assumed coverage on shares of Rockwell Medical in a report on Thursday, November 14th. They issued a “buy” rating and a $5.00 target price for the company. Finally, StockNews.com cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.

Rockwell Medical Trading Up 2.7 %

Shares of NASDAQ:RMTI opened at $2.31 on Monday. Rockwell Medical has a 52 week low of $1.16 and a 52 week high of $5.15. The company’s 50 day moving average is $3.53 and its two-hundred day moving average is $2.65. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. The company has a market cap of $74.66 million, a PE ratio of -47.20 and a beta of 1.50.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Concurrent Investment Advisors LLC acquired a new position in shares of Rockwell Medical in the 3rd quarter valued at $40,000. Verus Capital Partners LLC acquired a new stake in Rockwell Medical during the 3rd quarter worth $51,000. Barclays PLC acquired a new stake in Rockwell Medical during the 3rd quarter worth $90,000. Beacon Financial Advisory LLC acquired a new stake in Rockwell Medical during the 3rd quarter worth $98,000. Finally, XTX Topco Ltd boosted its stake in Rockwell Medical by 45.7% during the 3rd quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after purchasing an additional 8,922 shares during the period. Institutional investors and hedge funds own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.